Analysts cut Cardiome price target

Versant Partners and Dundee Securities have lowered their price targets on Cardiome Pharma (TSX:COM; NASDAQ:CRME) after it and partner Astellas Pharma halted a 470-patient Phase 3 trial testing an IV formulation of vernakalant or Kynapid for rapid-onset atrial fibrillation. Versant Partners analyst Doug Loe writes that the decision was “clearly disappointing because halting (the trial) [...]

Cardiome’s Kynapid trial suspended

Cardiome Pharma’s (NASDAQ: CRME; TSX:COM) co-development partner, Astellas Pharma U.S., has suspended patient enrolment in the ACT 5 study of Kynapid after an unexpected serious adverse event of cardiogenic shock experienced by a patient with atrial fibrillation who received the drug. The trial’s Data Safety Monitoring Board has reviewed the case and recommended the trial [...]

EU approves Cardiome’s Brinavess for IV

Cardiome Pharma’s (NASDAQ: CRME; TSX:COM) intravenous formulation of Brinavess has received marketing approval in the European Union, Iceland and Norway for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Patrick Magri, senior vice president, general manager, Cardiovascular Franchise, Merck (NYSE:MRK), said “we welcome this important milestone in our collaboration with [...]